Table 4: Adjusted odds ratios and 95% confidence intervals for specific cancers associated with antidiabetic drugs.

Site-specific cancerMetforminSulfonylureaInsulinAge-sex-adjusted odds ratioAge-sex-adjusted odds ratio
( )( )( ) (95% CI) (95% CI)
Cases/ %Cases/ %Cases/ %Insulin versus metforminSulfonylureas versus metformin

Breast*19/20480.9348/28041.715/3381.481.630 (0.604–4.396)1.765 (1.030–3.024)
Prostate*27/19151.4152/32681.595/4131.210.893 (0.338–2.359)1.034 (0.644–1.659)
Colon and rectum46/39631.16145/60722.3918/7512.402.135 (1.226–3.717)1.847 (1.320–2.585)
Lung45/39631.14122/60722.019/7511.201.058 (0.513–2.183)1.570 (1.110–2.220)
Liver58/39631.46143/60722.3619/7512.531.818 (1.075–3.077)1.504 (1.104–2.049)
Stomach20/39630.5054/60720.897/7510.931.855 (0.779–4.419)1.547 (0.923–2.594)
Pancreas8/39630.2021/60720.351/7510.130.693 (0.087–5.545)1.594 (0.705–3.619)

*Breast cancer and prostate cancer were only adjusted for age but not sex.